PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Both companies show declining cash positions (-16.72% vs TRAW's -28.26%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Cash + STI yoy 0.5-0.75x TRAW's -28.26%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of TRAW's 110.96%. David Dodd sees a leaner approach to short-term items.
-19.08%
0.5-0.75x TRAW's -28.85%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-14.24%
Similar yoy growth to TRAW's -15.13%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
0.5-0.75x TRAW's -14.02%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
0.5-0.75x TRAW's -28.75%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-4.20%
Less than half of TRAW's 1.58%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Less than half of TRAW's -64.91%. David Dodd sees fewer expansions in other current obligations.
18.79%
Less than half of TRAW's -2.73%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Above 1.5x TRAW's 6.40%. Michael Burry sees a potential leverage warning sign.
2.42%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-5.90%
≥ 1.5x TRAW's -2.47%. David Dodd sees higher yoy retained profits than competitor.
-12.27%
Less than half of TRAW's 16.13%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
Below half TRAW's -182.41%. Michael Burry sees potential underperformance in building shareholder capital.
-19.02%
0.5-0.75x TRAW's -28.75%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
50-75% of TRAW's 28.26%. Bruce Berkowitz notes comparatively lower net debt expansion.